glp-1 breastfeeding patch while Wholesale GLP-1 Patch™ Breastfeeding with GLP-1 Medication: Safety
Description
Food and Drug Administration (FDA) to treat individuals with type 2 diabetes mellitus and obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one other weight-related medical condition
doi: 10.1097/MCO.0b013e3283479109
Only semaglutide was associated with reduced depression and anxiety risk in patients without diabetes
But with that comes potential harms worth mentioning
The appetite suppression they produce is significant
(Product image courtesy of Novo Nordisk
